The Tumour Microenvironment: More Than Cancer Cells

The Main Components

Cancer-associated fibroblasts remodel the matrix, secrete growth factors and can build a physical barrier to drug and T-cell entry. Endothelial cells form an abnormal, leaky vasculature. Immune cells range from cytotoxic T cells and natural killer cells to suppressive regulatory T cells, tumour-associated macrophages and myeloid-derived suppressor cells.

The non-cellular environment includes a stiff, disorganised extracellular matrix, regions of low oxygen and low pH, and elevated interstitial fluid pressure that impedes drug delivery.

Support Versus Restraint

Many microenvironment signals promote tumour growth: angiogenic factors, matrix-degrading enzymes that enable invasion, and cytokines that support survival. Others restrain it, chiefly an effective cytotoxic immune response.

Tumours evolve to tip this balance, recruiting suppressive cells, inducing the adenosine pathway, and excluding or exhausting T cells.

Why It Matters for Treatment

The microenvironment explains many treatment failures. Dense stroma can block drug penetration in pancreatic cancer. Hypoxia reduces the effectiveness of radiotherapy and some drugs. An immunosuppressive infiltrate limits checkpoint-inhibitor benefit.

It also creates opportunities: anti-angiogenic drugs, agents that reprogramme macrophages, and stroma-targeting approaches all aim at the environment rather than the cancer cell itself. Sequential biopsies show the microenvironment changes under treatment pressure.

Reading the Microenvironment in Practice

Parts of the microenvironment are already measured routinely: PD-L1 and tumour-infiltrating lymphocytes for immunotherapy decisions, and stromal content in pancreatic and breast pathology. Spatial and single-cell profiling can map the environment in much more detail but are mostly research tools.

The environment also changes under treatment — anti-angiogenic therapy can transiently normalise vasculature and improve drug delivery, and successful immunotherapy shifts an infiltrate from suppressive to cytotoxic — which is why a pre-treatment biopsy may not describe the tumour a few months later, and why repeat sampling is increasingly used in trials.

Key Takeaways

• ·The tumour microenvironment includes fibroblasts, vasculature, immune cells and a modified matrix.
• ·Its signals both support tumour growth and, through cytotoxic immunity, restrain it.
• ·Stroma, hypoxia and immune suppression in the microenvironment underlie many treatment failures.